The ability of FASN-related cellular metabolism to confer endocrine resistance in ER/HER2+ breast cancer cells, provides strong rationale for incorporating next-generation FASN inhibitors in the therapeutic arsenal against de novo endocrine resistance in patients with ER+/HER2+ luminal B-like breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.